BJDX · NASDAQ
Bluejay Diagnostics, Inc.
$0.55 +0.01 (+1.80%)
Company overview
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force, as well as the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for monitoring disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infarction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NASDAQ
- Market cap
- $569,093
- Employees
- 7
- Headquarters
- Acton, MA
- Website
- bluejaydx.com
- CEO
- Indranil Dey
- Listed
- November 10, 2021
- P/E
- -0.03
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- -$98,367
- Operating income
- -$7M
- EBITDA
- -$6.8M
- Net income
- -$6.9M
- EPS
- -$16.32
- Total assets
- $5.6M
- Total debt
- $97,032
- Earnings yield
- -2,967.27%
BJDX
1D
NASDAQ
O0.57H0.58L0.54C0.54-0.03 (-5.08%)Vol11.37K